stockrow
Saturday 7 November 2026
Export NRSN’s income statement to Excel — free account
NeuroSense Therapeutics Ltd.
NRSN Healthcare Biotechnology
1.50
0.10
+7.14%
Follow NRSN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 3 | 3 | 15 | +132.9% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | (1) | (3) | (4) | (12) | (10) | (10) | (11) | (14) | +44.5% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (1) | (3) | (4) | (12) | (10) | (10) | (11) | (11) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (5.27) | (10.25) | (13.00) | (21.40) | (14.82) | (10.80) | (8.80) | (12.49) | +8.9% | ||||||
| Cash flow | — | — | — | (2.51) | (2.52) | (4.93) | (13.19) | (12.25) | (10.90) | (6.02) | 0.00 | +15.7% | ||||||
| Capex | — | — | — | (0.03) | (0.03) | (0.05) | (0.12) | (0.04) | 0.00 | (0.01) | 0.00 | (23.0%) | ||||||
| Free cash flow | — | — | — | (2.54) | (2.55) | (4.98) | (13.31) | (12.29) | (10.90) | (6.03) | 0.00 | +15.5% | ||||||
| Book value | — | — | — | 3.96 | 2.39 | 28.85 | 9.77 | (2.58) | 2.78 | (1.22) | 0.00 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 6 | +32.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (1) | (2) | (8) | (8) | (10) | (8) | (10) | +53.7% | |||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +2.3% | ||||||
| Free cash flow | — | — | — | (1) | (1) | (2) | (8) | (8) | (10) | (8) | (11) | +53.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | 1 | 11 | 6 | (1) | 2 | (2) | (2) | n/m | |||||
| Net debt | — | — | — | (1) | (1) | (11) | (7) | (3) | (3) | 0 | 0 | (26.5%) | ||||||
| Shareholders’ equity | — | — | — | 1 | 1 | 9 | 6 | (2) | 3 | (2) | (2) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (255.92) | (326.18) | (66.19) | (128.94) | (185.53) | (263.14) | (397.11) | 0.00 | (141.2) pt | |||||
| ROIC | — | — | — | (3,355.98) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +3,356.0 pt | ||||||
| ROE | — | — | — | 0.00 | (358.66) | (83.62) | (168.75) | (523.68) | (2,478.16) | (2,174.98) | 0.00 | (2,175.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 3 | 11 | 14 | 18 | 15 | 16 | — | +39.8% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
NeuroSense Therapeutics Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KALA KALA BIO, Inc. | $3.0M | — (loss-making) | — (loss-making) | −86.31% (below 0%: shrinking) | n/m | +80.19% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| JUNS Jupiter Neurosciences, Inc. | $2.8M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | Compare |
| AFMDQ Affimed N.V. | $2.8M | — (loss-making) | — (loss-making) | −92.02% (below 0%: shrinking) | n/m | +46.95% (above 0%: growing) | 100.00% | (9,216.90%) | Compare |
| DCOY Decoy Therapeutics Inc | $2.7M | — (loss-making) | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $2.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | |
| EOCN Eocene Ltd. | $2.6M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $2.5M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $2.7M | — | — | −85.46% | — | +15.94% | 100.00% | (527.99%) |